Protalix BioTherapeutics, Inc. (PLX) stock
Close on Nov 11, 2026Market cap $252.19MP/E 12.5Yield –
Protalix BioTherapeutics, Inc. grew revenue 37.0% to $84.69M over the twelve months to Sep 30, 2026. Operating income rose 295.9% to $25.21M, moving the operating margin from 10.3% to 29.8%. Free cash flow was $15.07M. At the latest close the market valued the company at $252.19M, 12.5 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $252.19M
- P/E ratio
- 12.5
- Price to sales
- 2.98
- Price to book
- 3.13
- Dividend yield
- –
- Free cash flow yield
- 5.97%
Fundamentals
- Revenue
- $84.69M
- Net income
- $20.55M
- EPS, diluted
- $0.25
- Free cash flow
- $15.07M
- Book value per share
- $0.96
- Diluted shares
- 84M
Trading
- Next earnings
- Mar 17, 2027 (estimated, before the open)
- Previous close
- $2.86
- Open
- $2.86
- Day's range
- $2.78 – $3.14
- Volume
- 3,092,811
- Average volume (20 days)
- 871,224
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 0.86
- 52-week range
- $1.65 – $3.19
- RSI (14 days)
- 71.2
- Volatility (1 year)
- 55.8%
- Relative volume
- 4.10×
- WACC
- 9.2%
On 1 of our idea list: Undervalued and financially sound
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PLX | S&P 500 | Difference | PLX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +12.6% | -2.4% | +15.0 pts | ||
| 3 months | +28.8% | -1.2% | +30.0 pts | ||
| Year to date | +73.9% | +12.3% | +61.6 pts | ||
| 1 year | +46.9% | +12.4% | +34.5 pts | ||
| 3 years | +133.6% | +78.8% | +54.8 pts | +32.7% | +21.4% |
| 5 years | +184.5% | +75.2% | +109.4 pts | +23.3% | +11.9% |
| 10 years | -34.8% | +311.1% | −345.9 pts | -4.2% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Protalix BioTherapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- News
About Protalix BioTherapeutics
Biological Products, (No Diagnostic Substances)
Protalix is a commercial stage biopharmaceutical company that discovers, develops, produces, and commercializes therapeutics for rare diseases using a plant cell-based protein expression system. Its commercial portfolio includes two enzyme replacement therapies: Elelyso for Gaucher disease and Elfabrio for Fabry disease. In addition, the company develops pipeline candidates for conditions such as uncontrolled gout and renal indications. Rather than selling directly to individual patients, the company supplies drug substance and finished products to pharmaceutical partners, specifically Pfizer, Chiesi, and Fiocruz, which handle global distribution.
Company profile, executives and historyProtalix BioTherapeutics stock: common questions
What is Protalix BioTherapeutics's stock price?
PLX closed at $3.13 on Nov 11, 2026, up 9.44% on the day. Over the past 52 weeks it traded between $1.65 and $3.19.
What is Protalix BioTherapeutics's market cap?
Protalix BioTherapeutics was worth $252.19M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PLX's P/E ratio?
PLX trades at 12.5 times earnings, based on diluted earnings per share of $0.25 over the twelve months to Sep 30, 2026.
How much revenue does Protalix BioTherapeutics make?
Protalix BioTherapeutics reported revenue of $84.69M for the twelve months to Sep 30, 2026, up 37.0% from a year earlier.
Does Protalix BioTherapeutics pay a dividend?
No. Protalix BioTherapeutics has not paid a cash dividend over the last twelve months.
When does Protalix BioTherapeutics report earnings next?
Protalix BioTherapeutics is expected to report Q4 FY2026 results on Mar 17, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has PLX stock performed over the past year?
Including dividends, PLX returned +46.9% over the past year, against +12.4% for the S&P 500.
How many PLX shares are sold short?
3M shares were sold short at the latest FINRA report, 4.49% of the float, or 6.2 days of average trading volume.
Who are Protalix BioTherapeutics's competitors?
Companies most similar to Protalix BioTherapeutics by business, industry and size include KYMR, FDMT, RXRX, MAZE, PTHS.
See a number that looks wrong?